IngredientesLactase (EC 3.2.1.108) is an enzyme produced by many organisms and is essential to the complete digestion of whole milk. It breaks down the sugar lactose into its component parts, galactose and glucose, simple sugars that can be absorbed into the bloodstream through an animal's intestines. A lactase is a type of β-galactosidase because it breaks down the β-glycosidic bond in D-lactose. The chemical reaction it catalyzes is: C₁₂H₂₂O₁₁ + H₂O → C₆H₁₂O₆ + C₆H₁₂O₆ + heat.
The only human gene encoding a lactase is LCT, or lactase-phlorizin hydrolase (alternative symbol LPH). LCT has a lactase domain and a phlorizin hydrolase domain, and it is encoded on chromosome 2. Lactase is found in the brush border of the small intestine of humans and other mammals.
Endogenous lactase in humans is produced by enterocytes lining the small intestinal villi. Lactose in milk is a rich nutrient for infants, who develop the ability to break it down into glucose and galactose by producing lactase in the brush border membrane of the small intestine. Lactase levels remain high during infancy, until weaning from the breast occurs, after which there is a gradual loss in the ability to digest milk due to a loss of ability to produce lactase — a condition called primary lactose intolerance (LI), also known as hypolactasia or lactase deficiency. Some people retain the ability to digest milk as adults; these individuals are referred to as lactase persistent or lactose tolerant.
For supplemental and industrial purposes, lactase is derived from microbial sources. Lactase is a β-galactosidase, with special importance for the production of lactose-free milk and dairy products. This enzyme is industrially obtained from fungal sources such as Aspergillus, Kluyveromyces, Trichoderma, Penicillium, Rhizopus, and Fusarium. Lactases are industrially obtained mainly from Aspergillus niger and Aspergillus oryzae and also from the yeasts Kluyveromyces marxianus and Kluyveromyces fragilis.
Notwithstanding the fact that bacteria Streptococcus thermophilus and Bacillus stearothermophilus can be used to produce lactase, yeasts and fungal sources are mainly responsible for the production of this enzyme. Kluyveromyces spp. — specifically K. marxianus, K. lactis, and K. fragilis — are the strains normally responsible for production in a lactose-rich medium.
The lactases produced by filamentous fungi are more heat-stable compared with those originating from yeasts. Fungal acid lactases are activated by acidification but perform poorly at the pH of milk. The A. oryzae acid lactase has a pH optimum at 4.5, and the pH optimum of the A. niger enzyme is at 3. The main application of acid lactases is as a dietary supplement where lactose hydrolysis takes place in the stomach.
As a dietary supplement, lactase is available in multiple forms:
The European Food Safety Authority (EFSA) and the United States Food and Drug Administration (USFDA) both approve and recommend Aspergillus oryzae as a source. Lactase from A. oryzae is considered GRAS (Generally Regarded as Safe).
Although it is estimated that the prevalence of lactase persistence greatly increased in Europe around 5,000 to 7,000 years ago, anthropological evidence, including bones of juvenile livestock and ancient pottery remains, places the cultural adoption of dairying as far back as 12,000 years ago. This suggests that for several thousand years, humans were milking sheep, goats, and cattle despite the inability to digest milk.
Animal milk use started between approximately 9,000 and 6,500 BCE at the onset of the Neolithic in Southwest Asia, and it subsequently accompanied the spread of farming into Europe from 6800/6700 BCE onward. Against the background of lambing seasons, climate, and technology, it is likely that prehistoric adults consumed not fresh milk but variants of lactose-reduced fermented milks and cheeses. This is well in line with genetic lactose intolerance prevailing in the Neolithic, though the strong selective force behind the regional emergence of genetic lactase persistence in later prehistory is still unknown.
Shards of ancient ceramic sieves provide clues as to how this was possible for early farmers and herders. Many Paleolithic and Neolithic cultures practiced the storage and transport of food and water in animal skins and intestines. When milk was introduced to the Neolithic diet in the Middle East, it was likely stored in an inflated cow stomach, resulting in the separation of the curds and whey. By using ceramic sieves to strain the curds and whey and ferment these dairy products into cheese, they were able to greatly reduce the level of lactose in their dairy products.
Not all populations whose ancestors had access to milk genetically adapted to become lactase persistent. Indeed, Central Asian herders are mostly lactase nonpersistent, despite their significant dietary reliance on dairy products. Central Asian herders are proposed to have adapted to milk consumption culturally, by fermentation, and/or by colonic adaptation, rather than genetically.
In European and many African, Middle Eastern, and southern Asian populations, lactase persistence (LP) is the most strongly selected monogenic trait to have evolved over the past 10,000 years. In mammals, lactase, the enzyme that hydrolyzes the milk sugar lactose, is normally down-regulated after weaning, but at least five human populations around the world have independently evolved mutations regulating the expression of the lactase-phlorizin-hydrolase gene. These mutations result in a dominant lactase persistence phenotype and continued lactase tolerance in adulthood. A single nucleotide polymorphism (SNP) at C/T-13910 is responsible for most lactase persistence in European populations.
Additional genetic pressures may have existed in arid climates where milk is one of the only clean sources of water, or in northern latitudes where, in the absence of vitamin D, the presence of lactose facilitates the absorption of calcium by the intestinal mucosa and thus reduces the risk of rickets and osteomalacia.
Traditionally, populations without lactase persistence who still consumed dairy have historically relied on fermentation as a practical tool. Milk fermentation, with origins dating back over 10,000 years, likely emerged as a means of preserving dairy products prior to the advent of refrigeration. These fermented products — including yogurts, kefirs, and aged cheeses — are naturally reduced in lactose because bacterial cultures produce their own β-galactosidases during fermentation.
The commercial development of exogenous lactase preparations as a dietary supplement became relevant in the twentieth century alongside industrialized dairy production and increased scientific understanding of enzyme biochemistry. It is well known to take a lactase preparation for the purpose of suppressing the symptoms of lactase intolerance, and lactase preparations have been manufactured and sold in many countries. The identification of microbial sources — particularly fungal and yeast strains — enabled scalable industrial production of food-grade lactase.
In biological hydrolysis reactions, like that of lactose, a water molecule splits the glycosidic bond of the polysaccharide into multiple monosaccharides. In this case, lactose is hydrolyzed to produce two monosaccharides, glucose and galactose.
The catalytic mechanism of D-lactose hydrolysis retains the substrate anomeric configuration in the products. While the details of the mechanism are uncertain, the stereochemical retention is achieved via a double displacement reaction. Studies of E. coli lactase have proposed that hydrolysis is initiated when a glutamate nucleophile on the enzyme attacks from the axial side of the galactosyl carbon in the β-glycosidic bond. The removal of the D-glucose leaving group may be facilitated by Mg-dependent acid catalysis. The enzyme is liberated from the α-galactosyl moiety upon equatorial nucleophilic attack by water, which produces D-galactose.
Substrate modification studies have demonstrated that the 3′-OH and 2′-OH moieties on the galactopyranose ring are essential for recognition and hydrolysis by the mammalian lactase. The 3′-hydroxy group is involved in initial binding to the substrate, while the 2′-group is not necessary for recognition but is needed in subsequent steps.
The catalytic activity of lactase is highly dependent on pH and temperature, which vary by enzyme source. Fungal β-galactosidase thrives in an acidic environment (pH 2.5–5.4), while yeast and bacterial counterparts function best at a more neutral pH (6.0–7.0). Kluyveromyces lactis produces neutral lactase, optimal for milk processing at pH 6–7. Kluyveromyces marxianus offers high growth rates and thermostable lactase variants suitable for processes requiring elevated temperatures. Aspergillus oryzae and Aspergillus niger produce acidic lactase, ideal for dairy fermentation products such as yogurt, kefir, and fermented beverages.
The absence of lactase determines both the excessive osmotic load in the small intestine and the fermentation of lactose by the bacterial flora with consequent production of short-chain fatty acids and gas. This latter process is responsible for the onset of symptoms associated with lactose intolerance (abdominal pain, bloating, flatulence, etc.), which arise after the intake of lactose.
Lactose intolerance is characterized by the presence of primarily gastrointestinal clinical signs resulting from colonic fermentation of lactose, the absorption of which is impaired due to a deficiency in the lactase enzyme. These clinical signs can be modified by several factors, including lactose dose, residual lactase expression, concurrent ingestion of other dietary components, gut-transit time, and enteric microbiome composition.
Approximately 65% of the human population has a reduced ability to digest lactose after infancy. Estimates from systematic reviews indicate the figure may be higher: a systematic review and meta-analysis by Storhaug, Fosse, and Fadnes (2017), searching studies from MEDLINE and Embase and including 62,910 participants from 89 countries, estimated the global prevalence of lactose malabsorption at 68%.
Lactase nonpersistence is most prevalent in people of East Asian descent, with 70 to 100% of people affected in these communities. Lactase nonpersistence is also very common in people of West African, Arab, Jewish, Greek, and Italian descent. Approximately 70% of the world's peoples are lactose intolerant. The incidence of primary LI is about 90% to 100% in Native Americans, Africans, and Asians. It is estimated to be 80% in African Americans and 55%–80% in Hispanics. The lowest incidence (10%–15%) occurs in those descended from northern Europeans, residents of the northwestern Indian subcontinent, and desert nomads.
Some patients with lactase persistence lose the ability to digest lactose as a result of environmental triggers — a condition known as secondary LI. Lactase production is confined to the upper third of the intestinal villi; due to its superficial location, conditions that affect villi often disrupt lactase production. Secondary LI may also be caused by celiac disease, malnutrition, irritable bowel syndrome (IBS), or intestinal surgery. Tetracyclines, neomycin, cimetidine, and antithyroid medications have all been implicated as causes.
This is the primary and best-evidenced clinical application of lactase supplementation. The mechanism is clear and direct: orally administered lactase hydrolyzes dietary lactose in the gastrointestinal tract, reducing the amount of intact lactose that reaches the colon for bacterial fermentation.
A randomized, double-blind, crossover placebo-controlled trial studied the effect of lactase chewable tablets on clinical symptoms and hydrogen breath excretion in patients with lactose intolerance confirmed by lactose hydrogen breath test (HBT). Clinical symptom severity was recorded using a visual analog scale, and HBT was performed every 30 minutes for 180 minutes. In the crossover design, the same patients were tested with both lactase and placebo, acting as their own controls with a washout period of one week. Forty-seven patients (mean age 33.6 years; 30 males) with lactose intolerance formed the study group. Clinical symptoms, mean clinical score (P < 0.05), and mean hydrogen breath levels (P < 0.05) were improved when the patients were given lactase.
Reduction in cumulative hydrogen breath level was 55% when patients received lactase compared to placebo. Maximum reduction took place in the final 30 minutes of the 3-hour period. The percentage reduction of hydrogen emitted in the breath monotonically increased with time, demonstrating that the efficacy of the drug increased over time.
A systematic review identified 36 unique randomized studies (26 on lactase- or lactose-hydrolyzed milk supplements, lactose-reduced milk, or tolerable doses of lactose; 7 on probiotics; 2 on incremental lactose administration for colonic adaptation; and 1 on another agent) that met inclusion criteria.
The Agency for Healthcare Research and Quality review of 28 RCTs of lactose-reduced and hydrolyzed formulations and lactase found insufficient evidence of effectiveness in reducing symptoms of lactose intolerance compared with lactose. In trials of patients with symptoms compatible with lactose intolerance, none of the four trials with control treatments of up to 12g of lactose found a significant improvement. This mixed result reflects the methodological heterogeneity in trials, including variation in lactase dose, lactose challenge amount, and outcome measures.
Moderate evidence from 21 RCTs suggested that increasing doses of lactose produce symptoms in patients with diagnosed lactose malabsorption, with or without self-reported symptoms, and the tolerable dose may differ if lactose is consumed with versus without other nutrients. Most trials indicated that patients with lactose intolerance or malabsorption could ingest 12g of lactose as a single dose with no or minor symptoms when administered as a single dose without other nutrients; doses of 15g to 18g seemed to be well-tolerated when given as a single dose with other nutrients.
Evidence strength for lactase supplementation in classic lactose intolerance symptom relief is moderate to good for reducing breath hydrogen (an objective measure of colonic fermentation) and mixed to insufficient for symptom relief in formal systematic review analyses, partly because of heterogeneity in study designs and the recognized difficulty of blinding in digestive enzyme trials.
A hypothesis that undigested lactose may contribute to infantile colic — excessive, unexplained crying in otherwise healthy infants — has motivated trials of lactase supplementation in this population.
A systematic review of RCTs analyzed the efficacy of lactase supplementation in infantile colic. PubMed, Embase, and Cochrane were searched for RCTs evaluating lactase supplementation in infants up to 6 months old with infantile colic. Out of six RCTs including 394 patients, three reported a significantly shorter crying time in the lactase group than in the placebo group, while the other three found no significant difference between groups. Of the two studies that performed the hydrogen breath test, only one reported a significant reduction in exhaled hydrogen levels.
The risk of bias was assessed using the revised Cochrane risk-of-bias tool. Five RCTs involving a total of 391 infants were identified. Three RCTs reported reduced crying duration, but one showed effect only in a compliant group (40.4%, p = 0.0052). A meta-analysis of two RCTs found no difference in crying duration and fussing time during one week of lactase treatment compared with placebo (mean difference −17.66 min/day, 95% CI −60.8 to 25.5; I² = 68%).
The risk of bias was low in only one RCT, high in three, and raised some concerns in one. While individual trials have shown some promise, the overall evidence for the efficacy of lactase supplementation in treating infant colic remains inconclusive. Further well-designed RCTs are necessary to determine the effects of lactase on managing infant colic.
A 2018 Cochrane systematic review considering dietary modification in infant colic treatment found that current evidence is insufficient to make any conclusion on the effectiveness of lactase supplementation in the management of infant colic.
Evidence strength for lactase in infantile colic is weak and inconclusive, with high risk of bias across most available trials.
Lactase supplementation has been explored in IBS patients, given that lactose malabsorption is common and may overlap with or exacerbate IBS symptoms. A double-blind, cross-over therapeutic clinical trial of the efficacy of exogenous, microbial β-D-galactosidase to reduce the symptoms of IBS was conducted in 12 patients whose customary diets regularly included milk. Eight of the 12 subjects (67%) proved to be lactase-nonpersistent. The study lasted 4 months; when symptoms during trial months were analyzed by the cumulative sum procedure, gastrointestinal symptoms were found to be independent of lactase treatment.
Limited evidence supports the use of lactase to target lactose in IBS, and evidence for such application is scant. The current picture suggests that lactase supplementation may reduce lactose-specific symptoms in IBS patients who are also lactose malabsorbers, but does not appear to have broader IBS therapeutic efficacy.
Evidence strength for lactase in IBS is weak and insufficient to draw firm clinical conclusions.
Because dairy products are a major dietary source of calcium, lactase deficiency — by predisposing individuals to dairy avoidance — has been theorized to indirectly affect bone mineral density.
Lactose intolerance may predispose individuals to low calcium intake as the number of lactose-free, calcium-rich food sources is limited. A review of data from human and animal studies on the influence of lactose and lactase deficiency on calcium absorption and bone health found that, based on the available evidence, neither dietary lactose nor lactase deficiency have a significant impact on calcium absorption in adult humans. However, lactose intolerance may lead to reduced bone density and fragility fractures when accompanied by decreased intake or avoidance of dairy. Recently published human trials and meta-analyses suggest a weak but significant association between dairy consumption and bone health, particularly in children.
The role of primary lactase deficiency (PLD) in postmenopausal osteoporosis development is not clear, but a published meta-analysis concluded that PLD is a risk factor for osteoporosis in postmenopausal women, and that these women need special attention in terms of screening for osteoporosis and its prevention.
One study in 46 postmenopausal subjects found malabsorption of lactose in 25 (54%) of subjects, associated with significantly lower milk intake. Malabsorption of calcium occurred in 11 (44%) of the lactase-deficient subjects and in 11 (52%) of normal lactose absorbers. There was no relationship between lactose and calcium malabsorption. Vertebral and forearm mineral densities were not significantly different between normal lactose absorbers and lactase-deficient subjects.
Research exploring the role of lactose intolerance on calcium intake and bone health has produced conflicting results. Studies involving perimenopausal Finnish women and postmenopausal Italian women found that lactase deficiency negatively impacted bone mineral density. Other studies, however, have not shown such an association. For example, Slemenda and associates found no evidence that lactase deficiency impacted bone density in pre- or postmenopausal women.
The overall evidence on lactase supplementation as a direct intervention to preserve bone health is indirect and preliminary. The primary concern is adequate calcium intake, rather than any direct effect of lactase on bone metabolism. Supplementing lactase to enable dairy consumption is viewed by some clinicians as a strategy to support calcium sufficiency in lactase-deficient individuals.
Two crossover clinical trials (Booster Alpha and Booster Omega) were performed in participants with lactose intolerance, where 2 × 10¹² CFUs of Bifidobacterium animalis subsp. lactis Bi-07, 4,662 FCC lactase, or placebo was consumed simultaneously with a lactose challenge, with 1-week washouts between challenges. Breath hydrogen concentration (BHC) was measured to assess the effect of the investigational products on lactose digestion, with incremental area under the curve (iAUC) as the primary outcome.
Lactase was superior to placebo in Booster Alpha (geometric least square mean ratio: 0.190; 95% CI: 0.102, 0.365; P < 0.001) but not Booster Omega. Noninferiority of Bi-07 compared with lactase was observed in Booster Omega. Odds of abdominal pain (compared with placebo: 0.32, P = 0.036) and flatulence (compared with placebo: 0.25, P = 0.007) were lower with lactase in Booster Alpha.
The primary site of action and clinical relevance of lactase is the gastrointestinal tract. The absence of lactase in the intestinal villi due to mucosal injury or genetic factors causes undigested lactose to reach the colon where it is fermented. Lactose intolerance is diagnosed based on clinical symptoms like bloating, abdominal pain and flatulence, lactose hydrogen breath test (HBT), and lactose tolerance test.
Four general principles exist in dealing with lactose intolerance: avoidance of dietary lactose, substitution to maintain nutrient intake, regulation of calcium intake, and use of enzyme substitute. Regular consumption of dairy food by lactase-deficient individuals may also reduce symptoms of intolerance by promoting colonic bacteria adaptation.
As discussed in Section 5.4, lactase deficiency creates a secondary risk to bone health through reduced dairy and calcium intake. Lactose intolerance may predispose individuals to low calcium intake as the number of lactose-free, calcium-rich food sources is limited. Lactase supplementation, by enabling dairy consumption, may indirectly support calcium intake, though direct evidence for a specific effect on bone outcomes is lacking.
In many individuals with lactose malabsorption, clinical signs may be absent after consumption of normal amounts of milk or, in particular, dairy products such as yogurt and cheese, which contain lactose partially digested by live bacteria. The intestinal microbiota can be modulated by biotic supplementation, which may alleviate the signs and symptoms of LI. The colonic microbial composition influences tolerance to lactose, and the relationship between lactase supplementation and the gut microbiome is an active area of inquiry.
Oral lactase supplements are typically dosed in FCC (Food Chemical Codex) units. The dosage is given in FCC units, which describes the enzyme activity — specifically, how much lactose can be broken down per minute under standardized conditions. FCC stands for Food Chemical Codex, a publication containing binding tests for food ingredients that list, among other things, tests that determine how many units of lactase are necessary for a certain number of grams of lactose to completely break down milk sugar.
Lactase supplements are generally most effective when taken immediately before or with the first bite of lactose-containing food. If still eating or drinking dairy products after 30–45 minutes, another dose may be needed, as per recommendations of a healthcare professional. For infant use, liquid drops are added to milk or formula prior to feeding.
Lactase has not been evaluated by the FDA as a drug, but is generally recognized as safe (GRAS) for human consumption. Lactase enzyme is marketed as a dietary supplement and does not require pre-marketing approvals from the FDA.
Lactase enzyme has no listed severe interactions with other drugs, no listed serious interactions with other drugs, and no listed moderate interactions with other drugs. Because lactase is a digestive enzyme acting locally in the gastrointestinal lumen, systemic pharmacokinetic interactions with pharmaceutical drugs are not expected by mechanism.
Certain metal ions, notably Fe²⁺, Zn²⁺, Cu²⁺, Pb²⁺, and Sn²⁺, can inhibit lactase activity. This is particularly relevant in industrial contexts where water or ingredient purity must be monitored. These inhibitors are unlikely to reach pharmacologically significant concentrations from a standard supplement consumer's perspective, but are noted as biochemical interactions relevant to formulation and industrial use.
Lactase enzyme has no documented adverse side effects in standard clinical use. Most users tolerate lactase supplements well. Some may notice mild digestive symptoms such as bloating or flatulence, especially if underlying lactose intolerance is severe and the supplement dose is insufficient. These symptoms are generally self-limiting. Though exceedingly rare, cases of true allergic reactions — including anaphylaxis — have been documented.
Pregnancy and lactation: Lactase enzyme is generally acceptable for use during pregnancy. Controlled studies in pregnant women show no evidence of fetal risk. Lactase may be used with breastfeeding.
Pediatrics: Lactase should not be administered to children younger than 4 years of age without checking with a pediatrician.
Product excipients: Some lactase enzyme products may contain aspartame, which should be avoided by people with phenylketonuria, a condition that causes inability to break down phenylalanine, an amino acid that aspartame contains.
Lactase enzyme is destroyed by high heat; it works best in warm milk or formula (i.e., at body temperature, approximately 98°F). Lactase infant drops should be added after milk or formula is prepared and is at body temperature; the milk should not be boiled with the lactase drops already mixed in.
For patients with secondary lactase deficiency, the cause of the underlying mucosal damage is significant. Injury to the intestinal mucosa can lead to secondary lactase deficiency, and resolution of the underlying cause may resolve the lactose intolerance. Management of lactose intolerance includes dietary modification, lactase supplementation, and treatment of underlying causes in secondary lactase deficiency. Secondary LI may be caused by celiac disease, malnutrition, irritable bowel syndrome, or intestinal surgery. Tetracyclines, neomycin, cimetidine, and antithyroid medications have all been implicated as causes.
EFSA and the USFDA both approve and recommend Aspergillus oryzae as a source for food-grade lactase. Lactase from A. oryzae is considered GRAS. Kluyveromyces lactis, Aspergillus niger, and Aspergillus oryzae provide food-grade enzyme safe for industrial use. Lactase activity in commercial preparations is standardized using the Food Chemical Codex (FCC), which specifies defined assay conditions for determining enzyme potency. This unit-based activity measurement is preferred over a simple weight-based dose because a pure weight specification says nothing about the activity of the enzymes, i.e., about their ability to break down lactose — there may be a given mass of lactase in a tablet, but some fraction of the enzyme may have already degraded during production.
Condiciones de salud que lactasa puede ayudar a apoyar.
Lactase deficiency causes undigested lactose to be fermented in the colon, generating gas and osmotic pressure that produce abdominal pain, cramping, bloating, and borborygmi. Multiple RCTs demonstrate that oral lactase supplementation significantly reduces these symptoms in lactose-intolerant individuals challenged with lactose. A randomized crossover placebo-controlled study confirmed statistically significant reductions in abdominal pain, bloating, and flatulence scores with lactase versus placebo.
Secondary lactose intolerance is highly prevalent in newly diagnosed celiac disease patients because intestinal villous damage reduces brush-border lactase enzyme levels. Oral lactase supplementation is recommended by CeD specialists while the gut heals on a gluten-free diet. Beth Israel Deaconess Medical Center, the National Celiac Association, and Beyond Celiac all explicitly cite oral lactase tablets as a management tool for CeD patients with concurrent lactose intolerance.
Lactase is the enzyme that hydrolyzes lactose into glucose and galactose, addressing lactose intolerance—a common cause of digestive discomfort in children (gas, bloating, diarrhea). Lactase enzyme supplementation and lactase-fortified infant formulas are used clinically to manage lactose intolerance and reduce GI symptoms in affected children. Evidence supporting lactase use in pediatric lactose maldigestion is well-established.
Transient lactase deficiency in infants has been proposed as a contributing factor to colic, with undigested lactose fermenting in the colon to produce gas and discomfort. Multiple RCTs have tested oral lactase supplementation in colicky infants with mixed results. A 2024 systematic review of six RCTs (n=394 infants) found that three studies reported shorter crying time with lactase, while three found no significant difference, leaving overall evidence inconclusive.
In lactose-intolerant individuals, insufficient lactase allows undigested lactose to reach the colon, where bacterial fermentation produces osmotic load and short-chain fatty acids that draw water into the colon, causing diarrhea. Exogenous lactase supplementation has been shown in RCTs and systematic reviews to significantly reduce lactose-induced diarrhea. A single dose of approximately 9,900 FCC units reduced breath hydrogen and symptoms including diarrhea compared to placebo.
Lactase (beta-galactosidase) hydrolyzes lactose into glucose and galactose and is the established treatment for lactose intolerance. Oral lactase supplements consistently reduce symptoms of lactose maldigestion such as bloating, gas, and diarrhea in RCTs. It is recognized by Johns Hopkins Medicine and other major institutions as a well-supported digestive enzyme supplement.
Lactase is the intestinal enzyme that hydrolyzes lactose; its deficiency is the direct cause of lactose intolerance, a highly prevalent food sensitivity. Multiple RCTs, including a crossover placebo-controlled trial (PMC7812489), show oral lactase supplementation significantly reduces GI symptoms and breath hydrogen excretion in lactose-intolerant individuals. It is recognized by Harvard Medical School, the NIH, and government health bodies as an established dietary management strategy.
Lactose malabsorption and IBS are considered independent conditions, yet many IBS patients report milk intolerance and symptom overlap. When dairy triggers IBS-like symptoms in confirmed lactose malabsorbers, lactase supplementation can improve dairy tolerance. However, a double-blind crossover trial and a PMC review found no conclusive evidence that lactase supplementation broadly benefits IBS as a functional disorder independent of confirmed lactose malabsorption.
Lactase (β-galactosidase) directly hydrolyzes lactose into glucose and galactose in the small intestine, the core enzymatic deficit in lactose intolerance. Multiple randomized controlled trials demonstrate that oral lactase supplementation significantly reduces breath hydrogen excretion and gastrointestinal symptoms. A double-blind crossover RCT (n=47) found a 55% reduction in cumulative hydrogen breath levels versus placebo. EFSA recognizes a health claim for lactase supplementation with dairy consumption.
Sistemas corporales que lactasa puede ayudar a apoyar.
Volver